VolitionRX Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $395.80K Miss $480.00K Estimate
Portfolio Pulse from totan@benzinga.com
VolitionRX (AMEX:VNRX) reported Q2 EPS of $(0.08), beating the $(0.09) estimate, but missed sales estimates with $395.80K against $480.00K. EPS improved by 42.86% YoY, and sales increased by 82.98% YoY.
August 14, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
VolitionRX reported better-than-expected EPS of $(0.08) against $(0.09) estimate, but missed sales estimates with $395.80K against $480.00K. EPS improved significantly YoY, and sales saw a substantial increase.
The better-than-expected EPS is a positive sign, but the miss on sales estimates could offset this. The significant YoY improvement in both EPS and sales is encouraging, but the mixed results may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100